In particular, we focused on the effect of AZD5363 (an AKT inhibitor), AZD2014 (an mTOR inhibitor), and BEZ235 (a dual PI3K/mTOR inhibitor) alone or in combination on two bladder cancer cell lines differing in their mTOR mutation status. The gene discussed is MTOR; the disease is urinary bladder carcinoma.